Cristina Teruzzi
Overview
Explore the profile of Cristina Teruzzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
21
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Drago V, Mele T, Patarnello F, Randon F, Teruzzi C, Drago F
Glob Reg Health Technol Assess
. 2025 Feb;
12:43-48.
PMID: 40018379
No abstract available.
2.
Di Matteo S, Freilone R, Bruno G, Notaro R, Moumene S, Martone N, et al.
Clinicoecon Outcomes Res
. 2024 Apr;
16:225-232.
PMID: 38623087
Background: Paroxysmal nocturnal hemoglobinuria is a rare, acquired disease characterized by hemolytic episodes and associated with significant clinical burden. The introduction of C5 inhibitory monoclonal antibodies (C5i) represented a major...
3.
Aiello A, Mariano E, Prada M, Teruzzi C, Martone N, Capri S, et al.
J Mark Access Health Policy
. 2023 Jul;
11(1):2230663.
PMID: 37405228
Primary immune thrombocytopenia is a rare autoimmune disease characterised by a decreased platelet count resulting in an increased risk of bleeding events and even life-threatening haemorrhages. Thrombopoietin receptor agonists (TPO-RAs)...
4.
Aiello A, Mancuso M, Leone S, Rossi L, Cioni L, Teruzzi C
Glob Reg Health Technol Assess
. 2023 Jan;
9:9-13.
PMID: 36628322
Haemophilia B (HB) is a rare disease which may lead to chronic disabling arthropathy, resulting in a significant clinical, social and economic impact. In recent years, new extended half-life (EHL)...
5.
Aiello A, Mancuso M, Colombo A, Teruzzi C, Berto P
Glob Reg Health Technol Assess
. 2023 Jan;
7:40-49.
PMID: 36627960
Introduction: Prophylaxis with factor IX (FIX) concentrates, produced by recombinant DNA technology (rFIX) or human plasma-derived concentrates, is the treatment of choice for haemophilia B (HB); rFIX covalently fused to...
6.
Gerace C, Montorsi F, Tambaro R, Carteni G, De Luca S, Tucci M, et al.
Clinicoecon Outcomes Res
. 2017 Aug;
9:433-442.
PMID: 28769578
Background: Urothelial bladder cancer (UBC) is the ninth most common cancer worldwide. In Italy, the prevalence of the disease is approximately 10%, making it the fourth most prevalent cancer in...
7.
Schinco P, Cultrera D, Valeri F, Borchiellini A, Mantuano M, Gorla F, et al.
Clinicoecon Outcomes Res
. 2015 Jan;
7:17-25.
PMID: 25565871
Purpose: Prophylaxis with von Willebrand factor (VWF)/factor VIII (FVIII) concentrates is a potential approach for patients with severe von Willebrand disease (VWD). As far as we are aware, to date...
8.
Karampampa K, Gustavsson A, Miltenburger C, Teruzzi C, Fattore G
Mult Scler
. 2012 May;
18(2 Suppl):29-34.
PMID: 22623125
No abstract available.